EyePoint Pharmaceuticals (NSDQ:EYPT) said today that it received $28.9 million in proceeds from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors and another accredited investor.
Last month, the Watertown, Mass.-based company won transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu, from the Centers for Medicare and Medicaid Services.
Get the full story at our sister site, Drug Delivery Business News.
The post EyePoint Pharmaceuticals raises $29m to fund Dexycu product launch appeared first on MassDevice.
from MassDevice https://ift.tt/2zMslmz
Cap comentari:
Publica un comentari a l'entrada